1
Liang Chang Dong, Patrick S L Wong, Atul Devdatt Ayer, Padmaja Shivanand, Michael A DesJardin: Osmotic dosage form composed of an extruded polymer tube form. ALZA Corporation, Samuel E Webb, December 10, 2002: US06491683 (32 worldwide citation)

A dosage form manufactured from an extruded polymer tube and method for manufacturing the dosage form are disclosed. The dosage form is preferably an osmotic dosage form and includes a therapeutic agent and an expandable composition contained within the lumen of the extruded polymer tube.


2
Thomas R Alessi, Michael A DesJardin, Stan Lam, Scott D Lautenbach, Pauline C Zamora: Osmotic delivery systems and piston assemblies for use therein. Intarcia Therapeutics, Gary R Fabian, Barbara G McClung, March 23, 2010: US07682356 (27 worldwide citation)

An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lu ...


3
Thomas R Alessi, Michael A DesJardin, Stan Lam, Scott D Lautenbach, Pauline C Zamora: Osmotic delivery systems and piston assemblies for use therein. Intarcia Therapeutics, Gary R Fabian, Barbara G McClung, February 1, 2011: US07879028 (20 worldwide citation)

An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lu ...


4
Catherine M Rohloff, Guohua Chen, Andrew S Luk, Rupal A Ayer, Paul R Houston, Michael A Desjardin, Pauline Zamora, Stan Lam: Solvent/polymer solutions as suspension vehicles. Intarcia Therapeutics, Gary R Fabian, Barbara G McClung, February 14, 2012: US08114437 (14 worldwide citation)

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be select ...


5
Paula Dennis, Michael A Desjardin, Stan Lam, Kui Liu, James E Matsuura, Latha Narayanan, Catherine M Rohloff, Pauline C Zamora: Implantable device for continuous delivery of interferon. Intarcia Therapeutics, Gary R Fabian, Barbara G McClung, February 2, 2010: US07655254 (13 worldwide citation)

An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 μg/day to maintain and achieve therapeutic blood or plasma levels of the interferon thro ...


6
Catherine M Rohloff, Guohua Chen, Andrew S Luk, Rupal A Ayer, Paul R Houston, Michael A Desjardin, Pauline Zamora, Stan Lam: Solvent/polymer solutions as suspension vehicles. Intarcia Therapeutics, Gary R Fabian, Barbara G McClung, June 26, 2012: US08206745 (12 worldwide citation)

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be select ...


7
Catherine M Rohloff, Guohua Chen, Andrew S Luk, Rupal A Ayer, Paul R Houston, Michael A Desjardin, Pauline Zamora, Stan Lam: Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles. Intarcia Therapeutics, Gary R Fabian, Barbara G McClung, July 3, 2012: US08211467 (11 worldwide citation)

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be select ...


8
Sylvia L Seroff, Noymi V Yam, Atul D Ayer, Padmanabh P Bhatt, Michael A Desjardin, Andrew C Lam, David E Edgren, Phillip R Nixon: Methods for providing effective reboxetine therapy with once-a-day dosing. Alza Corporation, October 7, 2003: US06630165 (11 worldwide citation)

Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plas ...


9
Scott D Lautenbach, Pedro E de la Serna, Pauline C Zamora, Michael A DesJardin: Two-piece, internal-channel osmotic delivery system flow modulator. Intarcia Therapeutics, Barbara G McClung, Gary R Fabian, April 17, 2012: US08158150 (10 worldwide citation)

An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery ...


10
Scott D Lautenbach, Pedro E de la Serna, Pauline C Zamora, Michael A DesJardin: Two-piece, internal-channel osmotic delivery system flow modulator. Intarcia Therapeutics, Gary R Fabian, Barbara G McClung, November 8, 2011: US08052996 (10 worldwide citation)

An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery ...